AstraZeneca India Q1 FY27 Revenue Grows 30% to ₹6,828 Mn

AstraZeneca Pharma India Ltd. announced its financial results for the quarter ended June 30, 2026, reporting a 30% year-on-year growth in total revenue from operations to INR 6,828 Mn. The company's performance was driven by its core therapy areas: Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Disease. Key financial highlights include a Profit before exceptional item and tax of INR 510 Mn and Profit after exceptional item and tax of INR 507 Mn. The company also received regulatory approvals for Acalabrutinib for Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) and Mantle cell lymphoma (MCL), and for Trastuzumab deruxtecan in HER2-positive breast cancer. Strategic initiatives include an MoU with the Government of Telangana for AI-enabled lung cancer screening and the launch of the K+ Connect initiative for hyperkalaemia management.